| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/22/1997 | CA2237783A1 E6 binding proteins |
| 05/22/1997 | CA2237565A1 Improved method and agents for inhibiting protein aging |
| 05/21/1997 | EP0774258A1 Composition containing 5-fluorouracil and d4T for use in the treatment of retroviral infection |
| 05/21/1997 | EP0774250A1 Use of a TNF alpha antagonist against skin redness of neurogenic origin |
| 05/21/1997 | EP0774005A1 Surface expression of enzyme in gene directed prodrug therapy |
| 05/21/1997 | EP0774003A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 05/21/1997 | EP0773959A1 Adrenergic receptor |
| 05/21/1997 | EP0773952A1 Interaction trap systems for detecting protein interactions |
| 05/21/1997 | EP0773795A1 Antifungal-wound healing compositions and methods for preparing and using same |
| 05/21/1997 | EP0684829A4 Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof. |
| 05/21/1997 | CN1150387A Pharmaceutical preparations and medicaments for prevention and treatment of endothelial dysfunction |
| 05/21/1997 | CN1150043A Efficient low-side effect external use medicine for curing seborrheic baldness |
| 05/20/1997 | US5631267 Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics |
| 05/20/1997 | US5631241 Wound healing agents of high molecular weight for eyes as antiinflammatory agents |
| 05/20/1997 | US5631015 Sustained release of drugs with bioabsorbable lactone polymer |
| 05/20/1997 | CA2112355C Improved process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| 05/16/1997 | CA2189097A1 Composition and method of treating retroviral infection |
| 05/15/1997 | WO1997017061A1 Therapeutic preparation for the transdermal administration of active substances |
| 05/15/1997 | WO1997016983A1 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 05/15/1997 | DE19542281A1 Verwendung von Epinastin für die Behandlung von Schmerzen Use of epinastine in the treatment of pain |
| 05/15/1997 | DE19541735A1 Use of hydrothermal rock deposits e.g. calcite precursors |
| 05/14/1997 | EP0773441A1 Molecules that home to a selected organ or tissue in vivo and methods of identifying same |
| 05/14/1997 | EP0772455A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 05/14/1997 | EP0772445A1 Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients |
| 05/14/1997 | EP0772442A1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 05/14/1997 | EP0772441A1 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
| 05/14/1997 | EP0772439A1 Novel antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections |
| 05/14/1997 | EP0772396A1 Method of regulating immune function |
| 05/14/1997 | EP0650365B1 Biocidal composition containing mustard seed plant extract |
| 05/14/1997 | CN1149828A Method for treating allergic rhinitis |
| 05/14/1997 | CN1149827A Agonists and antagonists of nicotinic acetylcholine receptors of insects to control endoparasites |
| 05/13/1997 | US5629436 Use of N-arylmethylene ethylenediaminetriacetates N-arylmethylene iminodiacetates or N,N'-diarylmethylene ethylenediamineacetates against oxidative stress |
| 05/13/1997 | US5629336 Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal |
| 05/13/1997 | US5629307 Use of ibogaine in reducing excitotoxic brain damage |
| 05/13/1997 | US5629305 Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| 05/13/1997 | US5629298 Increasing contractile performance, adenosine transport inhibitors used as potentiators |
| 05/13/1997 | US5629297 Administering ranitidine bismuth citrate and helicobacter inhibiting antibiotics |
| 05/13/1997 | US5629026 Gastric disorders |
| 05/13/1997 | US5629023 Nutrient composition increases hepatic detoxifying ability of the liver |
| 05/13/1997 | US5629015 Composition for combating ageing acting simultaneously on the surface layers and deep layers of the skin and use thereof |
| 05/13/1997 | US5628984 Composition to promote lung mucus secretions |
| 05/13/1997 | US5628979 Reagent for tumor imaging and therapy |
| 05/09/1997 | WO1997016549A2 Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands |
| 05/09/1997 | WO1997016455A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents |
| 05/09/1997 | WO1997016209A1 Expression of cyclin g1 in tumors |
| 05/09/1997 | WO1997016189A1 Combination therapy for the treatment of diabetes and obesity |
| 05/09/1997 | WO1997016185A2 A pharmaceutical composition for the treatment of autoimmune diseases |
| 05/09/1997 | WO1997016184A1 Method and pharmaceutical composition for regulating lipid concentration |
| 05/09/1997 | WO1997016177A1 Method of inhibiting cathepsin k |
| 05/09/1997 | WO1997016170A1 Treatment of a coronary condition by delivery of therapeutics to the pericardial space |
| 05/09/1997 | WO1997016169A1 Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| 05/09/1997 | WO1997016064A1 Methods and compositions for the reduction of xenotransplantation rejection |
| 05/09/1997 | CA2236297A1 Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands |
| 05/09/1997 | CA2209109A1 Method of inhibiting cathepsin k |
| 05/07/1997 | EP0771560A1 Use of 2- N-(1,2-benzoisothiazolyl-3(2H)one-1,1-dioxide ethyl 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropiridine-3-carboxylate in the treatment of vascular disorders |
| 05/07/1997 | EP0771323A1 Corticotropin-releasing factor-binding-protein inhibitors and their use |
| 05/07/1997 | EP0771215A1 Retroviral transduction of cells using soluble complement inhibitors |
| 05/07/1997 | EP0771207A1 Use of magnesium hydroxide as a stool softener |
| 05/07/1997 | EP0771203A1 Method of treating sweat-related conditions |
| 05/07/1997 | EP0771192A1 Use of anti-vegf agents in the treatment of endometriosis |
| 05/07/1997 | EP0771189A1 Inhalation composition |
| 05/07/1997 | EP0681578B1 Antiviral naphthoquinone compounds, compositions and uses thereof |
| 05/07/1997 | EP0667780A4 Purified ceramide-activated protein kinase, assay for identifying agents which act on same, and methods of using said agents. |
| 05/07/1997 | EP0628305B1 Stable oil-in-water emulsion type cosmetic or dermatologic composition containing at least one vegetable oil comprising at least 40% triglycerides derived from linolic acid |
| 05/07/1997 | DE19541260A1 Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut Therapeutic composition for transdermal administration of drugs through the skin |
| 05/06/1997 | US5627195 Tetrandrine |
| 05/06/1997 | US5627186 Treatment of htlv or aids with 4-amino-1-(2-hydroxymethyl oxathiolan-5-yl)-1h-pyrimidin-2-one with 3'-azido-3'-deoxy thymidine |
| 05/06/1997 | US5627168 Inhibition of the unidirectional efflux of the excitatory amino acid antagonist from the brain; antiepileptic and anxiolytic agents; schizophrenia, analgesics; neurodegenerative diseases |
| 05/06/1997 | US5627153 Anti-fungal methods and materials |
| 05/06/1997 | US5626880 Infusion preparation |
| 05/06/1997 | US5626862 Drug delivery from polymer matrices by release from matrix by degradation of polymer |
| 05/06/1997 | US5626860 Treatment of diabetes and reduction of fat stores |
| 05/06/1997 | US5626845 Method to ameliorate osteolysis and metastasis |
| 05/06/1997 | US5626838 Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| 05/02/1997 | EP0770876A1 A screening method for identifying ligands for target proteins |
| 05/02/1997 | EP0770627A1 Composition and methods using nitroxides to avoid oxygen toxicity |
| 05/02/1997 | EP0770399A2 Additives enhancing topical actions of therapeutic agents |
| 05/02/1997 | EP0770390A1 Nasally administrable compositions containing physiologically active peptides |
| 05/02/1997 | EP0770389A1 Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease |
| 05/02/1997 | EP0770135A1 Novel compounds |
| 05/02/1997 | EP0769967A1 Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
| 05/02/1997 | EP0769956A1 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| 05/02/1997 | EP0769939A1 Use of inhibitors of human s-cd23 |
| 05/02/1997 | EP0590024B1 Topical composition enhancing healing of herpes lesions |
| 05/01/1997 | WO1997015556A1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands |
| 05/01/1997 | WO1997015324A1 High fluorescence specific immune enhancing factor and methods of use for same |
| 05/01/1997 | WO1997015323A1 Infusions of neuroprotectants and thrombolytic agents |
| 05/01/1997 | WO1997015306A1 Infusions of neuroprotectants and perfluorochemicals |
| 05/01/1997 | WO1997015289A1 Solubilisation methods |
| 05/01/1997 | WO1997015281A1 Use of at least one beta-adrenergic agonist as a p substance antagonist |
| 05/01/1997 | WO1997015280A1 Use of at least one no synthase inhibitor for treating sensitive skin |
| 05/01/1997 | WO1997015269A2 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 05/01/1997 | WO1996028154A3 Use of anti-oestrogens as male contraceptives |
| 05/01/1997 | CA2235599A1 High fluorescence specific immune enhancing factor and methods of use for same |
| 05/01/1997 | CA2235487A1 Solubilisation methods |
| 05/01/1997 | CA2205534A1 Method, compositions and kits for increasing the bioavailability of pharmaceutical agents |
| 04/30/1997 | CN1148492A Treatment for arteriosclerosis and vitiligoidea |
| 04/29/1997 | US5625072 Retroviral protease inhibiting compounds |
| 04/29/1997 | US5624908 Antineoplastic compositions |
| 04/29/1997 | US5624893 Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |